RAMANDEEP BEHNIWAL: Open Payments
NPI 1508527458 · MOORPARK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$289 in 9 payments from 7 companies in 2025. Trend: 2023 $134 · 2024 $237 · 2025 $289
Food & beverage: $289
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| ABBVIE INC. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Soleno Therapeutics, Inc. | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: COBENFY, VRAYLAR, CAPLYTA, FANAPT, VYKAT XR, REJOYN, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
